From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Cavendish on Skinbiotherapeutics – I know how keen it is on Skins comment being “open source” so here is its note & forecasts

By Tom Winnifrith, the Sheriff of AIM | Friday 2 February 2024


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I know how keen the moronic weasel Giles Balleny at Cavendish is on all material regarding Skinbiotherapeutics (SBTX) being “open source” and so since his employer’s research notes are only available to a select few I reproduce the note out today below to help him out. There is no need to thank me for sparing you from the charge of a double standard, Giles, you knob. However, the note which covers the crap Dermatonics deal, I fear, begs more questions than it answers.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

Black-Swan

Video: Poking Bears And Black Swans

 

SBTX

Is Stuart Ashman lying again?

 

Crime-Scene

So farewell then MichaelWalters.com

Time left: 16:05:18